506 related articles for article (PubMed ID: 30400107)
1. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Merchant KM; Cedarbaum JM; Brundin P; Dave KD; Eberling J; Espay AJ; Hutten SJ; Javidnia M; Luthman J; Maetzler W; Menalled L; Reimer AN; Stoessl AJ; Weiner DM;
J Parkinsons Dis; 2019; 9(1):31-61. PubMed ID: 30400107
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
[TBL] [Abstract][Full Text] [Related]
3. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.
Rodger AT; ALNasser M; Carter WG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
Atik A; Stewart T; Zhang J
Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
[TBL] [Abstract][Full Text] [Related]
5. Therapeutics in the Pipeline Targeting
Grosso Jasutkar H; Oh SE; Mouradian MM
Pharmacol Rev; 2022 Jan; 74(1):207-237. PubMed ID: 35017177
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's and Lewy body dementia CSF biomarkers.
Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
[TBL] [Abstract][Full Text] [Related]
9. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
10. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
11. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
13. Animal models of α-synucleinopathy for Parkinson disease drug development.
Koprich JB; Kalia LV; Brotchie JM
Nat Rev Neurosci; 2017 Sep; 18(9):515-529. PubMed ID: 28747776
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease biomarkers based on α-synuclein.
Fayyad M; Salim S; Majbour N; Erskine D; Stoops E; Mollenhauer B; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):626-636. PubMed ID: 31265130
[TBL] [Abstract][Full Text] [Related]
15. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
16. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
Parnetti L; Cicognola C; Eusebi P; Chiasserini D
Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
[TBL] [Abstract][Full Text] [Related]
17. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?
Vernon AC; Ballard C; Modo M
Brain Res Rev; 2010 Oct; 65(1):28-55. PubMed ID: 20685363
[TBL] [Abstract][Full Text] [Related]
18. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
[TBL] [Abstract][Full Text] [Related]
19. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
Javed H; Kamal MA; Ojha S
CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
[TBL] [Abstract][Full Text] [Related]
20. Combination therapies: The next logical Step for the treatment of synucleinopathies?
Valera E; Masliah E
Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
